Search
Close this search box.

Vesper Bio: a sortilin-targeting pill to treat neurological disease

ARTICLE | Emerging Company Profile

Lundbeckfonden-backed start-up believes at-home oral therapy would offer benefits over injectables for genetically defined patients with dementia

By Paul Bonanos, Director of Biopharma Intelligence

February 28, 2024 2:55 AM UTC

Backed since its inception by Lundbeckfonden BioCapital, Danish start-up Vesper Bio has reached the clinic with what could be the first oral sortilin inhibitor to treat a genetically identified subset of patients with frontotemporal dementia.

With roots at Aarhus University, Vesper Bio ApS hopes to show that by inhibiting SORT1 with a brain-penetrant molecule, the company’s VES001 can maintain levels of PGRN and thus preserve neurological function in patients with heterozygous mutations in the GRN gene…